135 related articles for article (PubMed ID: 37422592)
1. Long-term outcomes in patients with Burkitt lymphoma older than 65 years: an analysis of the Texas Cancer Registry.
Burns EA; Wilson JJ; Mathur S; Kieser R; Gong Z; Hu CA; Tang CA; Petkova J; Yuen C; Mai H; Shah S; Rice L; Ganguly S; Pingali SR
Ann Hematol; 2023 Oct; 102(10):2753-2763. PubMed ID: 37422592
[TBL] [Abstract][Full Text] [Related]
2. Long term outcomes in older patients with primary central nervous system lymphoma: an analysis of the Texas Cancer Registry.
Burns EA; Sanchez CG; Mathur S; Guerrero C; Muhsen IN; Sarfraz H; Hu CA; Tang CA; Shah SS; Tremont IW; Teh B; Ganguly S; Pingali SRK
Ann Hematol; 2023 May; 102(5):1111-1120. PubMed ID: 36922432
[TBL] [Abstract][Full Text] [Related]
3. Burkitt lymphoma-a retrospective analysis of data from the Registry of the Czech Lymphoma Study Group with external validation of the Burkitt lymphoma International Prognostic Index.
Sýkorová A; Procházka V; Móciková H; Janíková A; Pytlík R; Belada D; Benešová K; Klener P; Ďuraš J; Smolej L; Campr V; Blahovcová P; Trněný M
Neoplasma; 2022 Dec; 69(6):1466-1473. PubMed ID: 36591807
[TBL] [Abstract][Full Text] [Related]
4. Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia.
Park YH; Kim WS; Kang HJ; Na II; Ryoo BY; Yang SH; Lee SS; Uhm JE; Kim K; Jung CW; Park K; Ko YH
Ann Hematol; 2006 May; 85(5):285-90. PubMed ID: 16518604
[TBL] [Abstract][Full Text] [Related]
5. Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab.
Zhu KY; Song KW; Connors JM; Leitch H; Barnett MJ; Ramadan K; Slack GW; Abou Mourad Y; Forrest DL; Hogge DE; Nantel SH; Narayanan S; Nevill TJ; Power MM; Sanford DS; Sutherland HJ; Tucker T; Toze CL; Sehn LH; Broady R; Gerrie AS
Br J Haematol; 2018 Jun; 181(6):782-790. PubMed ID: 29741758
[TBL] [Abstract][Full Text] [Related]
6. Prospective study of Burkitt lymphoma treatment in adolescents and adults in Malawi.
Painschab MS; Westmoreland KD; Kasonkanji E; Zuze T; Kaimila B; Waswa P; El-Mallawany NK; Tomoka T; Mulenga M; Montgomery ND; Fedoriw Y; Gopal S
Blood Adv; 2019 Feb; 3(4):612-620. PubMed ID: 30796065
[TBL] [Abstract][Full Text] [Related]
7. Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors.
Miralles P; Berenguer J; Ribera JM; Rubio R; Mahillo B; Téllez MJ; Lacruz J; Valencia E; Santos J; Rodríguez-Arrondo F; Pintado V;
J Acquir Immune Defic Syndr; 2007 Feb; 44(2):167-73. PubMed ID: 17117144
[TBL] [Abstract][Full Text] [Related]
8. Medical history, lifestyle, family history, and occupational risk factors for sporadic Burkitt lymphoma/leukemia: the Interlymph Non-Hodgkin Lymphoma Subtypes Project.
Mbulaiteye SM; Morton LM; Sampson JN; Chang ET; Costas L; de Sanjosé S; Lightfoot T; Kelly J; Friedberg JW; Cozen W; Marcos-Gragera R; Slager SL; Birmann BM; Weisenburger DD
J Natl Cancer Inst Monogr; 2014 Aug; 2014(48):106-14. PubMed ID: 25174031
[TBL] [Abstract][Full Text] [Related]
9. Survival of children with endemic Burkitt lymphoma in a prospective clinical care project in Uganda.
McGoldrick SM; Mutyaba I; Adams SV; Larsen A; Krantz EM; Namirembe C; Mooka P; Nabakooza S; Ndagire M; Mubiru K; Nabwana M; Nankinga R; Gerdts S; Gordon-Maclean C; Geriga F; Omoding A; Sessle E; Kambugu J; Uldrick TS; Orem J; Casper C
Pediatr Blood Cancer; 2019 Sep; 66(9):e27813. PubMed ID: 31157502
[TBL] [Abstract][Full Text] [Related]
10. Improved survival of Burkitt lymphoma/leukemia patients: observations from Poland, 1999-2020.
Caetano Dos Santos FL; Michalek IM; Wojciechowska U; Didkowska J; Walewski J
Ann Hematol; 2022 May; 101(5):1059-1065. PubMed ID: 35293608
[TBL] [Abstract][Full Text] [Related]
11. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
Thomas DA; Faderl S; O'Brien S; Bueso-Ramos C; Cortes J; Garcia-Manero G; Giles FJ; Verstovsek S; Wierda WG; Pierce SA; Shan J; Brandt M; Hagemeister FB; Keating MJ; Cabanillas F; Kantarjian H
Cancer; 2006 Apr; 106(7):1569-80. PubMed ID: 16502413
[TBL] [Abstract][Full Text] [Related]
12. In the South African setting, HIV-associated Burkitt lymphoma is associated with frequent leukaemic presentation, complex cytogenetic karyotypes, and adverse clinical outcomes.
Opie J; Antel K; Koller A; Novitzky N
Ann Hematol; 2020 Mar; 99(3):571-578. PubMed ID: 31955214
[TBL] [Abstract][Full Text] [Related]
13. Exhaustion of tumour-infiltrating T-cell receptor repertoire diversity is an age-dependent indicator of immunological fitness independently predictive of clinical outcome in Burkitt lymphoma.
Rieken J; Bernard V; Witte HM; Peter W; Merz H; Olschewski V; Hertel L; Lehnert H; Biersack H; von Bubnoff N; Feller AC; Gebauer N
Br J Haematol; 2021 Apr; 193(1):138-149. PubMed ID: 32945554
[TBL] [Abstract][Full Text] [Related]
14. Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas.
Fayad L; Thomas D; Romaguera J
Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 2():S57-62. PubMed ID: 18284717
[TBL] [Abstract][Full Text] [Related]
15. Inferior prognosis of gastric involvement in patients with gastrointestinal Burkitt Lymphoma.
Xie Y; Jia M; Shi J; Tao Y
Cancer Med; 2020 May; 9(9):3107-3114. PubMed ID: 32160410
[TBL] [Abstract][Full Text] [Related]
16. Stable Incidence and Poor Survival for HIV-Related Burkitt Lymphoma Among the US Veteran Population During the Antiretroviral Era.
Clark E; Royse KE; Dong Y; Chang E; Raychaudhury S; Kramer J; White DL; Chiao E
J Acquir Immune Defic Syndr; 2020 May; 84(1):18-25. PubMed ID: 32251095
[TBL] [Abstract][Full Text] [Related]
17. [Long term efficacy of COPADM regimen in the treatment of 20 patients with Burkitt lymphoma].
Yang D; Wang P; Chen J; Li CX; Zhang Y; Chen XC; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2018 Aug; 39(8):645-649. PubMed ID: 30180465
[No Abstract] [Full Text] [Related]
18. Outcomes for paediatric Burkitt lymphoma treated with anthracycline-based therapy in Malawi.
Stanley CC; Westmoreland KD; Heimlich BJ; El-Mallawany NK; Wasswa P; Mtete I; Butia M; Itimu S; Chasela M; Mtunda M; Chikasema M; Makwakwa V; Kaimila B; Kasonkanji E; Chimzimu F; Kampani C; Dhungel BM; Krysiak R; Montgomery ND; Fedoriw Y; Rosenberg NE; Liomba NG; Gopal S
Br J Haematol; 2016 Jun; 173(5):705-12. PubMed ID: 26914979
[TBL] [Abstract][Full Text] [Related]
19. Sporadic childhood Burkitt lymphoma incidence in the United States during 1992-2005.
Mbulaiteye SM; Biggar RJ; Bhatia K; Linet MS; Devesa SS
Pediatr Blood Cancer; 2009 Sep; 53(3):366-70. PubMed ID: 19434731
[TBL] [Abstract][Full Text] [Related]
20. Burkitt leukaemia/lymphoma: R-CODOX-M/R-IVAC remains gold standard treatment in BL.
Smyth L; Browne PV; Conneally E; Flynn C; Hayden P; Jeffers M; O'Brien D; Quinn F; Kelly J; Perera M; Crotty GM; Leahy M; Hennessy B; Jackson F; Ryan M; Vandenberghe E
Ir J Med Sci; 2016 Nov; 185(4):773-777. PubMed ID: 25843016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
